Patents by Inventor Kathleen A. Stringer

Kathleen A. Stringer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serum metabolites as biomarkers for carnitine treatment of sepsis
    Patent number: 12478603
    Abstract: Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: November 25, 2025
    Assignees: The Regents of the University of Michigan, The University of Mississippi Medical Center
    Inventors: Michael A. Puskarich, Alan E. Jones, Christopher E. Gillies, Theodore S. Jennaro, Kathleen A. Stringer
  • SERUM METABOLITES AS BIOMARKERS FOR CARNITINE TREATMENT OF SEPSIS
    Publication number: 20230130325
    Abstract: Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 27, 2023
    Inventors: Michael A. PUSKARICH, ALAN E. JONES, CHRISTOPHER E. GILLIES, THEODORE S. JENNARO, KATHLEEN A. STRINGER
  • Formulations for pulmonary delivery
    Publication number: 20030113271
    Abstract: Formulations for pulmonary delivery that include a protein and a non-physiological surfactant at or above the CMC of the surfactant, and methods for preparing and using the same.
    Type: Application
    Filed: December 24, 2002
    Publication date: June 19, 2003
    Applicant: University Technology Corporation
    Inventors: Derrick Katyama, Mark C. Manning, Kathleen A. Stringer, John E. Repine
  • Plasminogen activator as an anti-inflammatory agent
    Patent number: 6497877
    Abstract: Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Moreover, in in vivo models of inflammation, treatment with plasminogen activator reduces edema without inhibiting neutrophil infiltration in in vivo models of inflammation.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: December 24, 2002
    Assignee: University Technology Corporation
    Inventors: Kathleen A. Stringer, Brooks M. Hybertson, John E. Repine, Joe M. McCord